登录

艾伯维完成对Aliada Therapeutics的收购

AbbVie Completes Acquisition of Aliada Therapeutics

艾伯维 等信源发布 2024-12-11 22:17

可切换为仅中文


Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease, ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology to strengthen neuroscience pipeline and R&D capabilitiesNORTH CHICAGO, Ill., Dec. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics.

收购增加了潜在的阿尔茨海默病最佳疾病缓解疗法ALIA-1758和新型血脑屏障(BBB)交叉技术,以加强神经科学管道和研发能力北芝加哥,伊利诺伊州,2024年12月11日/PRNewswire/--AbbVie(纽约证券交易所:ABBV)今天宣布,它已经完成了对Aliada Therapeutics的收购。

Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in development for the treatment of patients with Alzheimer's disease and is currently in a Phase 1 clinical trial. ALIA-1758 utilizes a novel blood-brain barrier (BBB)-crossing technology that enhances delivery of targeted drugs into the central nervous system (CNS)..

Aliada的主要研究资产是ALIA-1758,一种抗焦谷氨酸淀粉样β(3pE-Aβ)抗体,正在开发用于治疗阿尔茨海默病患者,目前正在进行1期临床试验。ALIA-1758利用一种新型血脑屏障(BBB)穿越技术,增强了靶向药物向中枢神经系统(CNS)的传递。

'Alzheimer's disease poses a significant public health challenge, impacting millions worldwide and is becoming more prevalent as populations age,' said Dawn Carlson, M.D., M.P.H., vice president, neuroscience development at AbbVie. 'With the acquisition now complete, we look forward to advancing potentially disease-modifying therapies such as ALIA-1758 for Alzheimer's disease and bolstering our neuroscience discovery and development efforts by leveraging Aliada's novel CNS drug delivery platform.'.

艾伯维(AbbVie)神经科学发展副总裁、医学博士道恩·卡尔森(DawnCarlson)说,阿尔茨海默氏病(Alzheimer's disease)是一项重大的公共卫生挑战,影响着全球数百万人,并且随着人口老龄化而变得越来越普遍随着收购现已完成,我们期待着推进潜在的疾病缓解疗法,如ALIA-1758治疗阿尔茨海默氏病,并通过利用Aliada的新型中枢神经系统药物输送平台来支持我们的神经科学发现和开发工作。”

For additional background on the acquisition, please read the announcement press release here.

有关此次收购的更多背景信息,请阅读此处的公告新闻稿。

About AbbVie

关于AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.

AbbVie的使命是发现并提供创新药物和解决方案,以解决当今严重的健康问题,并应对未来的医疗挑战。我们致力于在几个关键治疗领域(免疫学、肿瘤学、神经科学和眼部护理)以及Allergan美学产品组合中的产品和服务,对人们的生活产生重大影响。

For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube..

有关AbbVie的更多信息,请访问www.AbbVie.com。在LinkedIn、Facebook、Instagram、X(以前的Twitter)和YouTube上关注@AbbVie。

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements.

就1995年《私人证券诉讼改革法案》而言,本新闻稿中的一些声明是或可能被视为前瞻性声明。单词“相信”、“期望”、“预期”、“项目”以及类似的将来动词或条件动词的表达和用法通常表示前瞻性陈述。

AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry.

AbbVie警告称,这些前瞻性声明存在风险和不确定性,可能导致实际结果与前瞻性声明中明示或暗示的结果存在重大差异。此类风险和不确定性包括但不限于知识产权的挑战、其他产品的竞争、研发过程中固有的困难、不利的诉讼或政府行为以及适用于本行业的法律法规的变化。

Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, 'Risk Factors,' of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q.

有关可能影响艾伯维运营的经济、竞争、政府、技术和其他因素的其他信息,请参见艾伯维2023年年度报告表10-K第1A项“风险因素”,该报告已提交给美国证券交易委员会,并由其随后的10-Q表季度报告更新。

AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. .

除法律要求外,AbbVie没有义务,特别拒绝因后续事件或事态发展而公开发布对前瞻性声明的任何修订。

SOURCE AbbVie

来源AbbVie